Please Wait
Applying Filters...
menu
    • menu
    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    Data Compilation
    #PharmaFlow

    Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

    Stock Recap
    #PipelineProspector

    Menu

    Cefprozil

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/06/2025 TAPI Technology & API Services
    Israel
    		 TEVA PHARMACEUTICAL INDUSTRIES LTD 17827 CEFPROZIL 2004-11-16 Active II N/A
    28/06/2025 Unimark Remedies
    India
    		 UNIMARK REMEDIES LTD 21471 CEFPROZIL USP 2008-03-15 Inactive II N/A